{
    "clinical_study": {
        "@rank": "153062", 
        "arm_group": [
            {
                "arm_group_label": "Nebivolol", 
                "arm_group_type": "Active Comparator", 
                "description": "Group A will be given Nebivolol 5 to 10mg per day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Group B will be given Placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the safety and effectiveness of the study drug\n      Nebivolol, in people who suffer with high blood pressure with Chronic Obstructive Pulmonary\n      Disease (COPD)."
        }, 
        "brief_title": "Safety Study of Nebivolol for COPD Patients", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "High Blood Pressure", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Lung Diseases", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study would be a randomized, placebo-controlled trial of 60 hypertensive patients with\n      documented COPD greater than age 40."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of high blood pressure and chronic obstructive pulmonary disease\n             (COPD)\n\n        Exclusion Criteria:\n\n          -  Asthma; Heart failur;\n\n          -  End stage kidney disease;\n\n          -  acute myocardial infarction,unstable angina, stroke or TIA within the past year;\n\n          -  Females who are pregnant, lactating or women of childbearing potential who are not\n             using approved method of contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939990", 
            "org_study_id": "11-0720"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "The placebo looks like the study drug but it does not contain active ingredients.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo is a sugar pill."
            }, 
            {
                "arm_group_label": "Nebivolol", 
                "description": "5 to 10mg per day", 
                "intervention_name": "Nebivolol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nebivolol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Chronic Obstructive Pulmonary Disease", 
        "lastchanged_date": "September 10, 2013", 
        "link": {
            "description": "clinical trials at the University of Chicago", 
            "url": "http://aura.uchicago.edu"
        }, 
        "location": {
            "contact": {
                "email": "cschlaff@medicine.bsd.uchicago.edu", 
                "last_name": "Carrie Schlaffer", 
                "phone": "773-702-2591"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60637"
                }, 
                "name": "University of Chicago Medical Center"
            }, 
            "investigator": {
                "last_name": "George L Bakris, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Nebivolol in Chronic Obstructive Pulmonary Disease", 
        "overall_contact": {
            "email": "cschlaff@medicine.bsd.uchicago.edu.edu", 
            "last_name": "Carrie Schlaffer", 
            "phone": "773-702-2591"
        }, 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "George Bakris, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "USA: University of Chicago IRB", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "blood pressure control will be assessed per collection of research data at protocol visits.", 
            "measure": "to assess blood pressure control", 
            "safety_issue": "Yes", 
            "time_frame": "baseline to 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939990"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "pulmonary function tests will be assessed at protocol visits", 
            "measure": "to assess pulmonary function tests", 
            "safety_issue": "Yes", 
            "time_frame": "baseline to 4 weeks"
        }, 
        "source": "University of Chicago", 
        "sponsors": {
            "collaborator": {
                "agency": "Forest Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}